Clinical Trial Update: 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C [Phase 2]

View source ↗

Summary

A Phase 2 trial in chronic hepatitis C completed, evaluating a 4-week nitazoxanide lead-in followed by 36 weeks of nitazoxanide plus peginterferon alfa-2a.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Nitazoxanide (nitazoxanide)
• Peginterferon alfa-2a (Pegasys) (peginterferon alfa-2a)

Snippet

Sponsor: Romark Laboratories L.C. | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED